Dapagliflozin Versus a Dipeptidyl Peptidase 4 Inhibitor (DPP4) Both Added to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM)- Impact on Health, Quality of Life and Costs in the Turkish Clinical Setting
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2096
https://www.valueinhealthjournal.com/article/S1098-3015(15)04172-8/fulltext
Title :
Dapagliflozin Versus a Dipeptidyl Peptidase 4 Inhibitor (DPP4) Both Added to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM)- Impact on Health, Quality of Life and Costs in the Turkish Clinical Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04172-8&doi=10.1016/j.jval.2015.09.2096
First page :
A607
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1513